Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Phase 1 Completed

58 enrolled

BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT02000947 2019-10-31

D4190C00006

Phase 1 Completed

459 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02179671 2019-08-02

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Phase 2 Completed

32 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02141347 2018-12-12

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Phase 1 Completed

65 enrolled

Other solid neoplasmThoracic

Part A and B: Advanced Solid Malignancies

NCT03085849 2018-12-10

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Phase 1 Completed

2 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT02040064 2016-06-09

GEFTREM

Phase 1 Completed

27 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00312975 2012-06-07

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

......SMARTEST Trial......

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

ABIMMUNE

CLOVER

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

ARCTIC

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Pulmonary sarcomatoid_MEDI4736+Treme

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

D4190C00006

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

GEFTREM

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)